ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...

ImmunityBio's Anktiva wins conditional EMA approval, but faces stiff competition and financial risks. Click for why IBRX ...

Bacteria may be the next frontier in cancer treatment, according to a team led by researchers at Penn State that devised a ...

Detailed price information for Artara Therapeutics Inc (TARA-Q) from The Globe and Mail including charting and trades.

Can the immune system cure cancer? Dr. Patrick Soon-Shiong discusses a paradigm shift using NK cells to treat tumors without ...

Protara Therapeutics shows promise with strong TARA-002 results and a solid cash runway. Click here to read my latest ...

Gene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected detalimogene voraplasmid (also known as ...

Memorial Sloan Kettering Cancer Center researchers continued to make strides against cancer in 2025. Learn about some of ...

The Alzheimer's Drug Discovery Foundation (ADDF) today announced two new members to its Board of Governors: Gavin Cook, Executive Director of Global Alzheimer's Disease Commercial, Patient Journey and ...

(NewsNation) — Can cancer be killed? Billionaire Dr. Patrick Soon-Shiong, who also owns the LA Times and co-owns the Los Angeles Lakers, says yes. Soon-Shiong’s ImmunityBio developed Anktiva, a ...

ImmunityBio ( ($IBRX) ) has issued an announcement. On December 12, 2025, ImmunityBio announced that the European Medicines Agency recommended ...

Large-scale technology transformations continue to fall short across Europe, not because organisations lack engineering ...